Home / Market News / $XTNT

$XTNT news and market catalysts

The 6 most recent market catalysts affecting $XTNT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

6 catalysts 3 high impact 1 bullish 4 bearish Healthcare
Nov 16, 2026 Corporate Catalyst Bearish Impact 95
Xtant Medical Reports Third Quarter 2026 Financial Results and Announces Board-led Strategic Review Process
Xtant Medical reported a substantial revenue decline from $33.3 million to $24.3 million and swung to a net loss of $3.6 million in Q3 2026, missing guidance for the second consecu…
Sep 2, 2026 Corporate Catalyst Bullish Impact 75
Xtant Medical Holdings shares are trading higher after LUCID CAPITAL MARKETS initiated coverage on the stock with a Buy rating and announced a $1 price target.
The initiation of coverage by a capital markets firm with a 'Buy' rating and a specific price target is a strong positive catalyst for a small-cap stock like Xtant Medical Holdings…
Sep 2, 2026 Corporate Catalyst Neutral Impact 65
LUCID CAPITAL MARKETS Initiates Coverage On Xtant Medical Holdings with Buy Rating, Announces Price Target of $1
LUCID CAPITAL MARKETS has initiated coverage on Xtant Medical Holdings (XTNT) with a 'Buy' rating and a $1 price target. This event is significant because new analyst coverage, esp…
Aug 11, 2026 Corporate Catalyst Bearish Impact 95
Xtant Medical Holdings shares are trading lower after the company reported worse-than-expected Q2 financial results and cut its fY26 sales guidance.
This headline represents a major corporate catalyst for Xtant Medical Holdings. The combination of a Q2 earnings miss and a downward revision of future sales guidance indicates a s…
Aug 11, 2026 Corporate Catalyst Bearish Impact 92
Xtant Medical Hldgs Q2 Adj. EPS $(0.03) Misses $(0.02) Estimate, Sales $23.031M Miss $24.875M Estimate
Xtant Medical Holdings (XTNT) announced Q2 results that significantly underperformed analyst expectations, with adjusted EPS missing by 50% and sales missing by 7.41%. This poor pe…
Aug 11, 2026 Corporate Catalyst Bearish Impact 75
Xtant Medical Hldgs Lowers FY2026 Sales Guidance from $101.000M-$105.000M to $99.000M-$103.000M vs $102.058M Est
Xtant Medical Holdings (XTNT) has lowered its sales guidance for fiscal year 2026 from an initial range of $101.000 million-$105.000 million to a new range of $99.000 million-$103.…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.